ATXS
Price
$12.93
Change
+$0.02 (+0.15%)
Updated
Dec 12 closing price
Capitalization
738.11M
82 days until earnings call
Intraday BUY SELL Signals
SYBX
Price
$1.11
Change
+$0.01 (+0.91%)
Updated
Dec 12 closing price
Capitalization
12.99M
Intraday BUY SELL Signals
Interact to see
Advertisement

ATXS vs SYBX

Header iconATXS vs SYBX Comparison
Open Charts ATXS vs SYBXBanner chart's image
Astria Therapeutics
Price$12.93
Change+$0.02 (+0.15%)
Volume$1.66M
Capitalization738.11M
Synlogic
Price$1.11
Change+$0.01 (+0.91%)
Volume$26.48K
Capitalization12.99M
ATXS vs SYBX Comparison Chart in %
ATXS
Daily Signal:
Gain/Loss:
SYBX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ATXS vs. SYBX commentary
Dec 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a StrongBuy and SYBX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 13, 2025
Stock price -- (ATXS: $12.91 vs. SYBX: $1.10)
Brand notoriety: ATXS and SYBX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 42% vs. SYBX: 65%
Market capitalization -- ATXS: $738.11M vs. SYBX: $12.99M
ATXS [@Biotechnology] is valued at $738.11M. SYBX’s [@Biotechnology] market capitalization is $12.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileSYBX’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • SYBX’s FA Score: 1 green, 4 red.
According to our system of comparison, both ATXS and SYBX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 3 TA indicator(s) are bullish while SYBX’s TA Score has 4 bullish TA indicator(s).

  • ATXS’s TA Score: 3 bullish, 4 bearish.
  • SYBX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than SYBX.

Price Growth

ATXS (@Biotechnology) experienced а -1.60% price change this week, while SYBX (@Biotechnology) price change was -4.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.68%. For the same industry, the average monthly price growth was +4.10%, and the average quarterly price growth was +64.61%.

Reported Earning Dates

ATXS is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Biotechnology (+0.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATXS($738M) has a higher market cap than SYBX($13M). ATXS YTD gains are higher at: 44.407 vs. SYBX (-21.429). SYBX has higher annual earnings (EBITDA): -11.43M vs. ATXS (-136.51M). ATXS has more cash in the bank: 228M vs. SYBX (15.6M). SYBX has less debt than ATXS: SYBX (0) vs ATXS (4.46M). ATXS has higher revenues than SYBX: ATXS (706K) vs SYBX (8K).
ATXSSYBXATXS / SYBX
Capitalization738M13M5,677%
EBITDA-136.51M-11.43M1,194%
Gain YTD44.407-21.429-207%
P/E RatioN/A6.36-
Revenue706K8K8,825%
Total Cash228M15.6M1,462%
Total Debt4.46M0-
FUNDAMENTALS RATINGS
ATXS vs SYBX: Fundamental Ratings
ATXS
SYBX
OUTLOOK RATING
1..100
7851
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
83
Overvalued
PROFIT vs RISK RATING
1..100
83100
SMR RATING
1..100
9693
PRICE GROWTH RATING
1..100
3789
P/E GROWTH RATING
1..100
10019
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (78) in the Biotechnology industry is in the same range as SYBX (83). This means that ATXS’s stock grew similarly to SYBX’s over the last 12 months.

ATXS's Profit vs Risk Rating (83) in the Biotechnology industry is in the same range as SYBX (100). This means that ATXS’s stock grew similarly to SYBX’s over the last 12 months.

SYBX's SMR Rating (93) in the Biotechnology industry is in the same range as ATXS (96). This means that SYBX’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for SYBX (89). This means that ATXS’s stock grew somewhat faster than SYBX’s over the last 12 months.

SYBX's P/E Growth Rating (19) in the Biotechnology industry is significantly better than the same rating for ATXS (100). This means that SYBX’s stock grew significantly faster than ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSSYBX
RSI
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
88%
Momentum
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
77%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 10 days ago
80%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 19 days ago
90%
Bearish Trend 9 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signal:
Gain/Loss:
SYBX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VIVK0.070.01
+14.55%
Vivakor
EME639.5812.56
+2.00%
EMCOR Group
MNSB20.670.29
+1.42%
MainStreet Bancshares
CBT68.550.02
+0.03%
Cabot Corp
CLB17.01-0.01
-0.06%
Core Laboratories

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with SYRE. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
-0.46%
SYRE - ATXS
48%
Loosely correlated
-0.87%
XENE - ATXS
48%
Loosely correlated
+0.51%
RGNX - ATXS
47%
Loosely correlated
-1.61%
ORKA - ATXS
46%
Loosely correlated
-3.79%
IRON - ATXS
44%
Loosely correlated
+0.81%
More

SYBX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYBX has been loosely correlated with NEUP. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if SYBX jumps, then NEUP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYBX
1D Price
Change %
SYBX100%
+1.85%
NEUP - SYBX
64%
Loosely correlated
-5.46%
BTAI - SYBX
37%
Loosely correlated
-5.48%
SBHMY - SYBX
34%
Loosely correlated
N/A
MDGL - SYBX
31%
Poorly correlated
+3.41%
LITS - SYBX
29%
Poorly correlated
-1.63%
More